You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
(Stockholm, Sweden, 22 December, 2021.) The Capital Region of Denmark (Region Hovedstaden) has now given official approval to Asarina Pharma to begin its phase IIa study in Tourette, following a four-month delay due to an administrative backlog
Full PDFAsarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study in Tourette Syndrome was delayed. We now expect our first patients to be included in the Study in December.”
Full PDF(Stockholm, 28 September 2021.) The publication of Asarina Pharma’s phase IIb study, including a post hoc analysis into Sepranolone for PMDD (Premenstrual dysphoric disorder), demonstrates that Sepranolone in a 10 mg dose did have a significant treatment effect compared with placebo, when examined in an extended 9-day analysis of symptom reduction. Senior PMDD Key Opinion…
Full PDF(Stockholm, 16 September, 2021.) An administrative backlog due to Covid-19 at The Capital Region of Denmark (Region Hovedstaden) is causing a delay of approx. 3 months to the initiation of Asarina Pharma’s phase IIa study in Tourette Syndrome. The study is now expected to start in December 2021 and be completed at the end of…
Full PDFAsarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, and the granting of our first US…
Full PDF